Paul v. Virginia (1868)

Paul v. Virginia was a landmark decision by the U.S. Supreme Court in 1868 that clarified the federal government's limited role in regulating insurance. This case established that insurance is not interstate commerce and, therefore, is not subject to federal regulation under the Commerce Clause of the U.S. Constitution.

Key features of Paul v. Virginia:

  • State Regulation: The decision upheld the traditional approach to insurance regulation, which delegated primary regulatory power to the individual states. This meant that states had the authority to regulate and oversee insurance companies operating within their borders.

  • Interstate Commerce: The Court ruled that insurance transactions are not part of interstate commerce, and therefore are not subject to federal regulation under the Commerce Clause of the U.S. Constitution. This decision established the foundation for the McCarran-Ferguson Act of 1945, which gave states the authority to regulate insurance.

  • Impact on Employee Benefits: The Paul v. Virginia decision has had a significant impact on the regulation of employee benefits, particularly in the areas of health and disability insurance. Because insurance is regulated at the state level, there is significant variation in the rules and regulations governing employee benefits across different states. This has made it challenging for employers to design and administer benefit plans that comply with all applicable state regulations.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.